The invention provides for treating HBV or HDV infection or inhibiting human sodium taurocholate co-transporting polypeptide (hNTCP) with a polymeric bile acid or salt thereof, and pharmaceutical compositions comprising a polymeric bile acid or salt thereof, and a second HBV or HDV medicament.

The invention provides for treating HBV or HDV infection or inhibiting human sodium taurocholate co-transporting polypeptide (hNTCP) with a polymeric bile acid or salt thereof, and pharmaceutical compositions comprising a polymeric bile acid or salt thereof, and a second HBV or HDV medicament.

A composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes Ganoderma, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes a Ganoderma extract, a red jujube extract, a longan extract and a lotus seed extract.

A composition for modulating intestinal permeability and/or treating and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes Ganoderma, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes a Ganoderma extract, a red jujube extract, a longan extract and a lotus seed extract.

The present invention provides the method and/or compositions for administering a therapeutically effective amount of ursodeoxycholic acid (UDCA) intravenously for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases. The present invention also relates to methods of intravenous administration of UDCA in a dose of about 15 mg/kg to about 200 mg/ kg at a dosage interval of once every 12 hours to once every 72 hours.

The present invention provides the method and/or compositions for administering a therapeutically effective amount of ursodeoxycholic acid (UDCA) intravenously for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases. The present invention also relates to methods of intravenous administration of UDCA in a dose of about 15 mg/kg to about 200 mg/ kg at a dosage interval of once every 12 hours to once every 72 hours.

Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided.

Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided.

Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided.

The present invention relates to methods and systems for predicting the likelihood of acute respiratory distress syndrome (ARDS) in adult subjects. The invention further relates to methods of treatment and identification of subjects with an increased likelihood of developing ARDS as determined by the disclosed methods.